[{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Slayback Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Azurity Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Jerome Stevens Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Acquisition","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Azurity Pharma \/ Jerome Stevens Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Jerome Stevens Pharmaceuticals"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Arbor Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Azurity Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Azurity Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Slayback Pharma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Lupin Ltd"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gabapentin Enacarbil","moa":"Voltage-gated calcium channel","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gabapentin Enacarbil","moa":"Voltage-gated calcium channel","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Slayback Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Mineralocorticoid receptor | Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Arbor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carmustine","moa":"RNA | DNA | Glutathione reductase","graph1":"Oncology","graph2":"Phase II","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Wafer","sponsorNew":"Arbor Pharmaceuticals \/ Arbor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Arbor Pharmaceuticals \/ Arbor Pharmaceuticals"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"EdiGene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Pharmaceuticals \/ EdiGene","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Pharmaceuticals \/ EdiGene"}]
Find Clinical Drug Pipeline Developments & Deals by Azurity Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
